PCOS Healthcare Trends · Evergreen explainer

Hair thinning and hormonal acne: the androgen connection, explained

Two of the most searched questions in this condition sound like opposites: why is hair growing where it is not wanted, and why is it thinning where it is? Add persistent acne that did not end with the teenage years, and many people assume three separate problems. In PCOS, now also called PMOS for polyendocrine metabolic ovarian syndrome, clinicians group all three under one heading, clinical hyperandrogenism, meaning visible signs of androgen effect on skin and hair. This piece explains how one hormone signal can produce opposite results in different follicles, what the largest evidence reviews actually found about acne and hair thinning in this condition, why the 2023 International Evidence-based Guideline treats each of these two signs more cautiously than excess hair growth, and which clinician handles which part of the conversation.

One signal, three different answers

Androgens are a group of hormones present in all sexes. Skin and hair follicles do not all answer them the same way, and that single fact explains most of the confusion around this topic:

The word susceptible is doing real work in that list. Follicle sensitivity varies from person to person and runs in families, which is why visible signs and blood results do not always move together. A person can have acne or thinning with androgen levels inside the laboratory reference range, and a person can have raised androgens with clear skin and full hair. Extra insulin can be part of the picture too, because it can raise androgen activity and lower SHBG, the protein that keeps some androgen inactive. Our explainer on insulin resistance in PCOS/PMOS walks through that link in plain steps, and a 2025 narrative review in Cureus on acne in this condition describes the same two drivers, androgen effect compounded by insulin resistance, as the mechanism its authors found across the literature.

Acne in this condition: what the big reviews found

Acne in PCOS/PMOS is usually described as adult acne that persists past the teenage years or returns after a clear stretch, often alongside other features of the condition. Descriptions in the literature often mention the lower face and jawline, but no distribution on its own confirms or rules out a hormone link, and the guideline notes there is no universally accepted instrument for grading acne in this assessment. Clinicians describe what they see, where it is, and how severe it appears, rather than reading a single standard score the way they can for excess hair growth.

Two large meta-analyses give the scale of it, and reading them side by side teaches something about evidence as well as about skin:

Those two headlines, 43 percent and 49 percent, are not in conflict once the methods are visible: different study sets, different regions and ages, different diagnostic definitions, and one analysis adjusting for the tendency of striking results to be published more often. The honest summary is that acne is common in this condition, roughly twice as common as in comparison groups in the largest pool, more common in adolescents than adults, and variable enough by setting that no single percentage describes any one clinic, let alone any one person.

Hair thinning: the pattern clinicians look for

Female pattern hair loss in this condition is usually a slow, diffuse thinning over the top and crown of the scalp. The earliest change people report is a widening centre part, then visible scalp under bright light, and a ponytail that feels smaller than it used to. The front hairline is usually preserved, which is one reason the change can be well advanced before it is named. It is a pattern of gradual miniaturisation, not a sudden shedding.

That pattern matters because other kinds of hair loss look different and point elsewhere, and a good workup separates them:

For grading, the 2023 guideline points clinicians to standardised visual scales: the Ludwig scale, which grades loss of density over the crown in three stages, and the Olsen scale, which describes a triangular widening of the part toward the front, sometimes called a Christmas tree pattern. A grade recorded the same way at each visit, or dated photographs taken in the same light and parting, tell a clinician more than comparing the shower drain from week to week, because normal daily shedding varies and is a poor measure of pattern change.

The guideline is careful with these two signs, and says why

The 2023 International Evidence-based Guideline lists acne, female pattern hair loss and hirsutism together as the signs a complete history and examination should cover in adults. It then ranks their diagnostic weight differently, in one of its most quoted recommendations: healthcare professionals could recognise that female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. Hirsutism alone, by contrast, should be considered predictive of it. Our explainer on how PCOS/PMOS is diagnosed sets out where androgen excess sits in the 2-of-3 rule these signs feed into, and our piece on the four PCOS/PMOS phenotypes shows the combinations that rule produces.

Weak predictor needs translating, because it is often misread as does not matter. It means this: acne alone, or thinning alone, does a poor job of forecasting what an androgen blood test will show. Both are common, both have many causes, and both frequently occur with hormone levels in the reference range. So neither sign, on its own, settles a diagnosis, and neither should be waved away either. The guideline makes that second half explicit in a separate recommendation: clinicians should be aware of the potential negative psychosocial impact of clinical hyperandrogenism, and should consider a report of unwanted excess hair growth or female pattern hair loss as important regardless of apparent clinical severity. In plain terms, if thinning is distressing you, that distress and the pattern you describe belong in the record even when the loss looks early or mild in the room.

What a 2025 review of hair loss and PCOS found, in both directions

In 2025, researchers published a systematic review and meta-analysis in JAAD International that asked the association question both ways. Searching the literature to December 2024, they included 24 observational studies. In the 18 studies that assessed hair loss in patients with PCOS (3,464 patients), the pooled prevalence of female pattern hair loss was 22.7 percent, with a 95 percent confidence interval of 16.9 to 29.7 percent. In the 6 studies that assessed PCOS in patients with hair loss (1,583 patients), the pooled prevalence of PCOS was 32.3 percent, with a much wider interval of 13.6 to 59.1 percent.

The authors graded their own certainty, and an honest explainer keeps those grades attached: low certainty for the first figure, because the studies were very inconsistent with each other, and very low certainty for the second, with serious risk of bias added. They also noted that both conditions are probably underdiagnosed in the underlying studies, and that the designs were cross-sectional, a snapshot rather than a follow-up, so the review shows association, not cause, and cannot say whether having this condition makes hair loss faster or more severe for any individual. Read plainly, the review supports two modest conclusions: about one in five to one in four people with PCOS in these study groups had pattern hair loss, which also means most did not; and PCOS is common enough among people presenting with pattern hair loss that asking about cycles and other features is a reasonable part of that workup.

Why both signs are judged in months, not weeks

Patients often ask how soon a change should be visible, and the honest answer starts with biology rather than with any product. Scalp hair grows in long cycles, and a follicle that has miniaturised does not announce a change of direction quickly; clinicians grading pattern loss therefore talk in seasons, comparing the same scale grade or the same dated photograph months apart. Skin turns over faster than hair, but acne also fluctuates with cycles, stress, illness and products, so a single good or bad week is weak evidence about any direction. This page makes no claim about what any treatment, medicine or product does for either sign. What it can say is that the useful question at a follow-up visit is a measurement question: can we grade or photograph this the same way we did last time, and what change, over what period, would we count as real? Our guide to questions to bring to a first appointment shows how to set that record up from the first visit.

Which clinician handles which part

Our piece on which clinician does what maps that team in full, including dietitians and reproductive endocrinologists.

What this does not mean

Questions to bring to an appointment about acne or hair thinning

What this means when you are finding care

The clinician you want can name which kind of acne or hair loss you have, grade it with a standard scale where one exists, explain why blood work does or does not follow from it, and state plainly what would make them look for a different cause. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state, for example the Florida listings page, and skim the plain-language glossary before a visit.

Sources

Looking for care? Find a PCOS/PMOS-focused provider or browse by state.

This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.